ATTENDING COMPANIES INCLUDE
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
pariatur aliqua
Anim excepteur cillum irure reprehenderit non. Pariatur adipisicing labore ut mollit. Veniam officia veniam.
Bringing together ANTIBODY ENGINEERING, ADC Connect, and TIDES of Innovation, the ANTIBODY & TIDES SUMMIT 2025 is where antibody power meets TIDES precision
Launching in September:
IMAPAC's answer to the increasing demand for more effective biologic therapies.
Get ready! IMAPAC is heading to Amsterdam for the inaugural ANTIBODY & TIDES 2025 summit.
As the demand for more effective and diverse biologic therapies increases, TIDES of Innovation and the Antibody Engineering summit will address the key innovations driving the industry forward. From antibody discovery and engineering to biomanufacturing and emerging modalities, this event will provide a platform to discuss both the scientific advancements and industry challenges shaping the future of biotherapeutics
The biologics industry faces rising complexity in antibody development, necessitating smarter manufacturing and optimised regulatory compliance. With biotherapeutics growing more sophisticated, industry leaders are looking for solutions to scale production, reduce costs, and meet heightened regulatory demands without compromising quality.
These challenges are compounded by the evolving landscape of biologics, where the focus is shifting toward more personalised and potent treatments. At the same time, market competition is intensifying, and the push for cost-effective manufacturing processes continues to gain urgency
Thought leaders, industry influencers, and research specialists from biopharma, biotech, and CDMOs, will come together for these co-located events to explore critical advancements across the entire biologics lifecycle. From discovery and engineering through to biomanufacturing and commercialisation, this summit will provide a comprehensive view of the state-of-the-art innovations driving the future of biologic therapies.
WHO
R&D, CMC, and manufacturing leaders driving the development and delivery of:
- Monoclonal & Bispecific Antibodies
- Antibody-Drug Conjugates (ADCs)
- Peptides, Oligonucleotides & RNA-based therapeutics (TIDES)
Typical attendees include:
- Biotech & Pharma: Heads of Discovery, Process Development, CMC, and Outsourcing
- CDMOs, CROs & Tech Providers offering specialised services in complex biologics and TIDES
- Academic & Translational Researchers at the cutting edge of modality innovation
WHAT
A cross-functional summit uniting two powerful modalities –complex antibodies and TIDES – to explore shared challenges in:
- Early-stage R&D and candidate optimisation
- Scalable, cost-effective manufacturing
- Regulatory and analytical advancements
- Partnership and outsourcing strategy
Not just another biologics event – this is where science, CMC, and strategy converge for the most promising modular therapies in Europe.
WHY
- Modality innovation is booming – but the path from lab to patient is more complex than ever
- Antibodies and TIDES face similar hurdles in developability, manufacturability, and delivery
- Europe’s biotech ecosystem is rich in discovery, but needs smarter pathways to scale
- There’s no other dedicated platform in Europe bringing these two advanced modalities together to address shared bottlenecks and build partnerships
Key Themes & Topics
At the heart of the first ANTIBODY & TIDES SUMMIT, the programme is set to cover the full spectrum of antibody and biologics innovation:
ANTIBODY DISCOVERY & ENGINEERING:
Covering cutting-edge methods like phage display and single-cell sequencing for antibody identification, with AI improving stability and binding.
Explore bispecific antibodies and Fc-engineering to enhance efficacy and half-life, exemplified by AstraZeneca’s T-cell engager therapies.
BIOMANUFACURING & SCALE UP:
Addressing scaling up biologic production, with a focus on optimising processes, increasing yields, and ensuring regulatory compliance.
AI and continuous manufacturing, including the FDA’s PAT framework, will be discussed, with Lonza’s modular systems as a key example.
EMERGING MODALITIES:
Exploring new biologic therapies like bispecific antibodies, ADCs, engineered cytokines, and immune modulators, this theme highlights innovations in targeting precision and therapeutic potency, including Roche’s Mosunetuzumab for relapsed lymphoma.
REGULATORY CONSIDERATIONS:
Navigating regulatory pathways for biologics, including the FDA’s Breakthrough Therapy designation and EMA’s PRIME programme, with a focus on CMC compliance, stability studies, and recent monoclonal antibody approvals in the EU.
COMMERCIALISATION STRATEGIES:
Focusing on strategies for market entry, this theme covers partnerships, pricing, and biosimilar competition, using Amgen’s portfolio of biologics and biosimilars to demonstrate market leadership.
At the heart of the first ANTIBODY & TIDES SUMMIT, the programme is set to cover the full spectrum of antibody and biologics innovation:
ANTIBODY DISCOVERY & ENGINEERING:
Covering cutting-edge methods like phage display and single-cell sequencing for antibody identification, with AI improving stability and binding.
Explore bispecific antibodies and Fc-engineering to enhance efficacy and half-life, exemplified by AstraZeneca’s T-cell engager therapies.
BIOMANUFACURING & SCALE UP:
Addressing scaling up biologic production, with a focus on optimising processes, increasing yields, and ensuring regulatory compliance.
AI and continuous manufacturing, including the FDA’s PAT framework, will be discussed, with Lonza’s modular systems as a key example.
EMERGING MODALITIES:
Exploring new biologic therapies like bispecific antibodies, ADCs, engineered cytokines, and immune modulators, this theme highlights innovations in targeting precision and therapeutic potency, including Roche’s Mosunetuzumab for relapsed lymphoma.
REGULATORY CONSIDERATIONS:
Navigating regulatory pathways for biologics, including the FDA’s Breakthrough Therapy designation and EMA’s PRIME programme, with a focus on CMC compliance, stability studies, and recent monoclonal antibody approvals in the EU.
COMMERCIALISATION STRATEGIES:
Focusing on strategies for market entry, this theme covers partnerships, pricing, and biosimilar competition, using Amgen’s portfolio of biologics and biosimilars to demonstrate market leadership.
What to Expect at the ANTIBODY & TIDES 2025 Summit:
300 max
Small, focused gathering, limited to no more than 300 people to keep it intimate, ensuring that every conversation is valuable. This event is about real partnerships and progress.
60+
Focused content tailored to your needs from 60+ expert speakers. With 3 distinct streams every session focuses on relevant topics that are impacting the industry now – no fluff.
16+
16 hours of curated networking – building long-term partnerships: This is about bringing together the right people in a setting that encourages open dialogue and trust-building
24
24 interactive sessions to build understanding, exchange ideas, discuss trends that matter, and gain insights into the challenges and goals for 2025 and beyond
Attendees from 100+ Organisations participating in discussion on the development and significance of TIDE therapeutics and antibody engineering.
60+ Expert Speakers across both programmes, presenting on critical advancements in biologic therapies.
Over 16 hours of dedicated face-to-face networking, including 1:1 meetings and interactive sessions
